Deutsche Bank: Eli Lilly At 'Critical Stage' In Its Journey

by Jayson Derrick

August 27, 2014 12:55 PM | 2 min read | Make a Comment

Gregg Gilbert of Deutsche Bank initiated coverage of Eli Lilly PFE on Wednesday with a Buy rating and $70 price target. “Lilly is at a critical stage in its journey, dealing with loss of exclusivity for large products with a keen eye on costs, while investing to deliver new products to the market,” Gilbert wrote in a note to clients on Wednesday. “With a strong diabetes portfolio, under-the-radar oncology franchise opportunity, and recently-bolstered animal health segment, we believe Lilly is poised for return to growth in years ahead.” Lilly remains a leader in the diabetes market, despite the market becoming increasingly competitive over recent years. The company's diabetes franchise generated $4.2 billion in sales in 2013, representing 18 percent of the company's total revenue. Gilbert is projecting Lilly will increase its diabetes related sales to $7.2 billion in 2018 which will represent 29 percent of total revenue. According to the analyst, new launches from Jardiance will see peak sales of $500 million in sales by 2018, SGLT2/DPP4 and dulaglutide will see peak sales of $500 million and $850 million, respectively in 2019. Finally, basal insulin peglispro will see peak sales of $600 million by 2020. Lilly also has compelling oncology assets, according to Gilbert. The analyst sees a “solid opportunity” in Cyramza, which only recently saw regulatory approval for patients suffering from gastric cancer. The analyst estimates Cyramza will see peak sales of roughly $2 billion by 2020. Lilly plans to seek approval for a second line combination therapy for gastric cancer in addition to other novel product candidates in clinical development, including necitumumab in Phase 3 and abemaciclib which is expected to begin a Phase 3 trial soon. Beyond diabetes and oncology, Lilly has a late state pipeline that includes other therapeutic categories, including auto-immune, cardiovascular, musculoskeletal, and neuro-degenerative diseases. Finally, Lilly's animal health division provides the company with a form of stability through durable cash flows and a highly leveragable business model with margin expansion opportunities.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: News Diabetes Gregg Gilbertm Eli Lilly

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Benzinga.com on devices